A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.
СтатьяСравнительное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brangel Polina, Tureli Sina, Mühlemann Barbara, Liechti Nicole, Zysset Daniel, Engler Olivier, Hunger-Glaser Isabel, Ghiga Ioana, Mattiuzzo Giada, Eckerle Isabella, Bekliz Meriem, Rössler Annika, Schmitt Melanie M, Knabl Ludwig, Kimpel Janine, Tort Luis Fernando Lopez, de Araujo Mia Ferreira, de Oliveira Any Caroline Alves, Caetano Braulia Costa, Siqueira Marilda Mendonça, Budt Matthias, Gensch Jean-Marc, Wolff Thorsten, Hassan Tarteel, Selvaraj Francis Amirtharaj, Hermanus Tandile, Kgagudi Prudence, Crowther Carol, Richardson Simone I, Bhiman Jinal N, Moore Penny L, Cheng Samuel M S, Li John K C, Poon Leo L M, Peiris Malik, Corman Victor M, Drosten Christian, Lai Lilin, Hunsawong Taweewun, Rungrojcharoenkit Kamonthip, Lohachanakul Jindarat, Sigal Alex, Khan Khadija, Thiel Volker, Barut G Tuba, Ebert Nadine, Mykytyn Anna Z, Owusu Donkor Irene, Aboagye James Odame, Nartey Prince Adom, Van Kerkhove Maria D, Cunningham Jane, Haagmans Bart L, Suthar Mehul S, Smith Derek, Subissi Lorenzo
Аннотация
Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment of SARS-CoV-2 antigenicity. In this study, with the contribution of 15 independent laboratories across all WHO regions, we carried out a controlled analysis of neutralisation assay platforms using the first WHO International Standard for antibodies to SARS-CoV-2 variants of concern (source: NIBSC). Live virus isolates (source: WHO BioHub or individual labs) or spike plasmids (individual labs) for pseudovirus production were used to perform neutralisation assays using the same serum panels. When comparing fold drops, excellent data consistency was observed across the labs using common reagents, including between pseudovirus and live virus neutralisation assays (RMSD of data from mean fold drop was 0.59). Utilising a Bayesian model, geometric mean titres and assay titre magnitudes (offsets) can describe the data efficiently. Titre magnitudes were seen to vary largely even for labs within the same assay group. We have observed that overall, live Microneutralisation assays tend to have the lowest titres, whereas Pseudovirus Neutralisation have the highest (with a mean difference of 3.2 log2 units between the two). These findings are relevant for laboratory networks, such as the WHO Coronavirus Laboratory Network (CoViNet), that seek to support a global surveillance system for evolution and antigenic characterisation of variants to support monitoring of population immunity and vaccine composition policy.